Determinants of mortality in systemic sclerosis: a focused review

Rheumatology International

Volumn 38, Issue 10, 2018, Pages 1847-1858

  Poudel, Dilli Ram ^a   Jayakumar, Divya ^b   Danve, Abhijeet ^c   Sehra, Shiv Tej ^d   Derk, Chris T ^e  

^a Reading Health System   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT AUBURN HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Mortality; Predictor; Review; Scleroderma; Survival; Systemic sclerosis

Indexed keywords

ALL CAUSE MORTALITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LUNG DISEASE; MALIGNANT NEOPLASM; MORBIDITY; MORTALITY RATE; PRIORITY JOURNAL; REVIEW; SURVIVAL PREDICTION; SYSTEMIC SCLEROSIS; COMPLICATION; FIBROSIS; LOCALIZED SCLERODERMA; MORTALITY; TRENDS;

FIBROSIS; HUMANS; MORBIDITY; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC;

EID: 85033401284     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-017-3826-y     Document Type: Review

References (98)

1. Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37–50
2. Varga J (2016) Etiology and pathogenesis of scleroderma. In: Kelley Firestein’s textbook of rheumatology, vol 2, 10th edn. Elsevier/Saunders, Philadelphia
3. Wigley FM (2016) Clinical features & treatment of scleroderma. In: Kelley Firestein’s textbook of rheumatology, vol 2, 10th edn. Elsevier/Saunders, Philadelphia
4. Mukerjee D, St G, Coleiro B, Knight C, Denton C, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088–1093. doi:10.1136/ard.62.11.1088
5. Tamaki T, Mori S, Takehara K (1991) Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 283:366–371
6. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66:754–763. doi:10.1136/ard.2006.062901
7. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246–2255. doi:10.1002/art.11073
8. Altman RD, Medsger TA, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413. doi:10.1002/art.1780340405
9. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944. doi:10.1136/ard.2006.066068
10. Medsger TA (1971) Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75:369. doi:10.7326/0003-4819-75-3-369
11. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F et al (2013) Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore) 92:191–205. doi:10.1097/MD.0b013e31829be125
12. Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS et al (1993) Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 118:602. doi:10.7326/0003-4819-118-8-199304150-00005
13. Bryan C, Knight C, Black CM, Silman AJ (1999) Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 42:2660–2665. doi:10.1002/1529-0131(199912)42:12%3c2660:AID-ANR23%3e3.0.CO;2-N
14. Walsh SJ, Fenster JR (1997) Geographical clustering of mortality from systemic sclerosis in the Southeastern United States, 1981–90. J Rheumatol 24:2348–2352
15. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B, Medsger TA, Lucas M, Michet CJ et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118:2–10. doi:10.1016/j.amjmed.2004.04.031
16. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44:208–219. doi:10.1016/j.semarthrit.2014.05.010
17. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y (2012) Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 51:1017–1026. doi:10.1093/rheumatology/ker269
18. Psarras A, Soulaidopoulos S, Garyfallos A, Kitas G, Dimitroulas T (2017) A critical view on cardiovascular risk in systemic sclerosis. Rheumatol Int 37:85–95. doi:10.1007/s00296-016-3530-3
19. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M et al (2015) Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death. Medicine (Baltimore) 94:e1728. doi:10.1097/MD.0000000000001728
20. Meier FMP, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360. doi:10.1136/annrheumdis-2011-200742
21. Steen VD, Medsger TA (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133:600–603
22. Steen VD, Costantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352–357
23. Boin F, Rosen A (2007) Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep 9:165–172
24. Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD et al (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62:335–352
25. Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32:649–655
26. Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP (1984) Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76:779–786
27. Eason RJ, Tan PL, Gow PJ (1981) Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med 11:657–662
28. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM Mon J Assoc Physicians 100:485–494. doi:10.1093/qjmed/hcm052
29. Teixeira L, Mouthon L, Mahr A, Berezné A, Agard C, Mehrenberger M et al (2008) Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67:110–116. doi:10.1136/ard.2006.066985
30. Helfrich DJ, Banner B, Steen VD, Medsger TA (1989) Normotensive renal failure in systemic sclerosis. Arthritis Rheum 32:1128–1134
31. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL et al (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983–2989. doi:10.1002/art.10589
32. Kohno K, Katayama T, Majima K, Fujisawa M, Iida S, Fukami K et al (2000) A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment. Clin Nephrol 53:479–482
33. Steen VD, Medsger TA (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41:1613–1619. doi:10.1002/1529-0131(199809)41:9%3c1613:AID-ART11%3e3.0.CO;2-O
34. Guillevin L, Bérezné A, Seror R, Teixeira L, Pourrat J, Mahr A et al (2012) Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatol Oxf Engl 51:460–467. doi:10.1093/rheumatology/ker271
35. Abbott KC, Trespalacios FC, Welch PG, Agodoa LYC (2002) Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 15:236–240
36. Gibney EM, Parikh CR, Jani A, Fischer MJ, Collier D, Wiseman AC (2004) Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 4:2027–2031. doi:10.1111/j.1600-6143.2004.00605.x
37. Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP et al (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56:3837–3846. doi:10.1002/art.22965
38. Becker MO, Riemekasten G (2016) Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol 12:115–135. doi:10.1586/1744666X.2016.1115717
39. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81:139–153
40. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815. doi:10.1136/ard.2009.114264
41. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J (1989) Heart disease in systemic sclerosis. Semin Arthritis Rheum 19:191–200
42. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69:218–221. doi:10.1136/ard.2008.103382
43. Allanore Y, Meune C (2010) Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 28:S48–S53
44. Meune C, Vignaux O, Kahan A, Allanore Y (2010) Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 103:46–52. doi:10.1016/j.acvd.2009.06.009
45. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD et al (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56:2740–2746. doi:10.1002/art.22747
46. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L et al (2008) Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 58:1803–1809. doi:10.1002/art.23463
47. de Groote P, Gressin V, Hachulla E, Carpentier P, Guillevin L, Kahan A et al (2008) Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 67:31–36. doi:10.1136/ard.2006.057760
48. Kahan A, Allanore Y (2006) Primary myocardial involvement in systemic sclerosis. Rheumatol Oxf Engl 45(Suppl 4):iv14–iv17. doi:10.1093/rheumatology/kel312
49. D’Andrea A, Stisi S, Bellissimo S, Vigorito F, Scotto di Uccio F, Tozzi N et al (2005) Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr J Work Group Echocardiogr Eur Soc Cardiol 6:407–418. doi:10.1016/j.euje.2005.01.002
50. Steen V, Medsger TA (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516–522. doi:10.1002/art.10775
51. Chu S-Y, Chen Y-J, Liu C-J, Tseng W-C, Lin M-W, Hwang C-Y et al (2013) Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Am J Med 126:982–988. doi:10.1016/j.amjmed.2013.06.025
52. Nordin A, Jensen-Urstad K, Björnådal L, Pettersson S, Larsson A, Svenungsson E (2013) Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case–control study. Arthritis Res Ther 15:R87. doi:10.1186/ar4267
53. Kotnur MR, Suresh P, Reddy VSP, Sharma T, Salim NA (2016) Systemic sclerosis with multiple pulmonary manifestations. J Clin Diagn Res JCDR 10:OD16–OD17. doi:10.7860/JCDR/2016/18781.8032
54. Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE (1996) Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 90:223–230
55. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:D42–D50. doi:10.1016/j.jacc.2013.10.032
56. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:D34–D41. doi:10.1016/j.jacc.2013.10.029
57. Yang X, Mardekian J, Sanders KN, Mychaskiw MA, Thomas J (2013) Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 32:1519–1531. doi:10.1007/s10067-013-2307-2
58. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME et al (2014) Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 66:489–495. doi:10.1002/acr.22121
59. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M et al (2013) Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 65:2412–2423. doi:10.1002/art.38029
60. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM et al (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569–577. doi:10.1002/art.24267
61. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123:344–350
62. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L et al (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54:3043–3050. doi:10.1002/art.22069
63. Michelfelder M, Becker M, Riedlinger A, Siegert E, Drömann D, Yu X et al (2017) Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol 36:381–390. doi:10.1007/s10067-016-3504-6
64. Scotton CJ, Chambers RC (2007) Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132:1311–1321. doi:10.1378/chest.06-2568
65. Hunninghake GW, Kalica AR (1995) Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 151:915–918. doi:10.1164/ajrccm/151.3_Pt_1.915
66. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708–719. doi:10.1016/S2213-2600(16)30152-7
67. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666. doi:10.1056/NEJMoa055120
68. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD et al (2007) Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 56:1676–1684. doi:10.1002/art.22580
69. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J et al (2008) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 177:91–98. doi:10.1164/rccm.200705-655OC
70. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087. doi:10.1056/NEJMoa1103690
71. Gyger G, Baron M (2015) Systemic sclerosis: gastrointestinal disease and its management. Rheum Dis Clin N Am 41:459–473. doi:10.1016/j.rdc.2015.04.007
72. Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S (1973) Esophageal dysfunction in collagen disease. Am J Med Sci 265:191–199
73. Akesson A, Wollheim FA (1989) Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 28:281–286
74. Krause L, Becker MO, Brueckner CS, Bellinghausen C-J, Becker C, Schneider U et al (2010) Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 69:1951–1957. doi:10.1136/ard.2009.123273
75. Mecoli C, Purohit S, Sandorfi N, Derk CT (2014) Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. J Rheumatol 41:2049–2054. doi:10.3899/jrheum.131547
76. Derk CT, Rasheed M, Artlett CM, Jimenez SA (2006) A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 33:1113–1116
77. Rosenthal AK, McLaughlin JK, Linet MS, Persson I (1993) Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 52:531–533
78. Olesen AB, Svaerke C, Farkas DK, Sørensen HT (2010) Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 163:800–806. doi:10.1111/j.1365-2133.2010.09861.x
79. Pontifex EK, Hill CL, Roberts-Thomson P (2007) Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 66:551–553. doi:10.1136/ard.2006.056424
80. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA (2011) Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 70:104–109. doi:10.1136/ard.2009.127621
81. Strickland G, Pauling J, Cavill C, Shaddick G, McHugh N (2013) Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 32:1533–1539. doi:10.1007/s10067-013-2289-0
82. Woodworth TG, Suliman YA, Furst DE, Clements P (2016) Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 12:678–691. doi:10.1038/nrneph.2016.124
83. Al-Dhaher FF, Pope JE, Ouimet JM (2010) Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 39:269–277. doi:10.1016/j.semarthrit.2008.06.002
84. Alba MA, Velasco C, Simeón CP, Fonollosa V, Trapiella L, Egurbide MV et al (2014) Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) 93:73–81. doi:10.1097/MD.0000000000000018
85. Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE et al (2017) Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 37:75–84. doi:10.1007/s00296-015-3382-2
86. Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C et al (2016) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol Hoboken NJ. doi:10.1002/art.40027
87. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG et al (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis: pulmonary complications and survival in SSc. Arthritis Rheumatol 66:1625–1635. doi:10.1002/art.38390
88. Domsic RT, Nihtyanova SI, Wisniewski SR, Fine MJ, Lucas M, Kwoh CK et al (2014) Derivation and validation of a prediction rule for two year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol Hoboken NJ 66:1616–1624. doi:10.1002/art.38381
89. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J et al (2009) Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology 48:304–308. doi:10.1093/rheumatology/ken488
90. Nietert PJ, Silverstein MD, Silver RM (2001) Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 28:2031–2037
91. Komócsi A, Vorobcsuk A, Faludi R, Pintér T, Lenkey Z, Költo G et al (2012) The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatol Oxf Engl 51:1027–1036. doi:10.1093/rheumatology/ker357
92. Hinchcliff M, Desai CS, Varga J, Shah SJ (2012) Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol 30:S30–S37
93. Assassi S, del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A et al (2009) Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Care Res 61:1403–1411. doi:10.1002/art.24734
94. Draeger HT, Assassi S, Sharif R, Gonzalez EB, Harper BE, Arnett FC et al (2013) Right bundle branch block: a predictor of mortality in early systemic sclerosis. PLoS One 8:e78808. doi:10.1371/journal.pone.0078808
95. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67:59–63. doi:10.1136/ard.2006.066340
96. Sehra ST, Kelly A, Baker JF, Derk CT (2016) Predictors of inpatient mortality in patients with systemic sclerosis: a case control study. Clin Rheumatol 35:1631–1635. doi:10.1007/s10067-016-3245-6
97. Chung L, Krishnan E, Chakravarty EF (2007) Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatol Oxf Engl 46:1808–1813. doi:10.1093/rheumatology/kem273
98. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D (2014) International scleroderma renal crisis study investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey. Semin Arthritis Rheum 43:666–672. doi:10.1016/j.semarthrit.2013.09.008